Non-regulatory
announcement
21 March 2024
ONDINE BIOMEDICAL INC.
("Ondine Biomedical",
"Ondine" or the "Company")
Steriwave study shows 77%
drop in antibiotic use
Ondine Biomedical Inc. (LON:OBI), the Canadian life
sciences company pioneering light-activated antimicrobial
treatments to prevent and treat healthcare-associated infections
(HAIs), announces that a UK-based study demonstrated a significant
reduction in antibiotic use following sinus surgeries where
Steriwave® was used for pre-surgical nasal decolonization.
Professor Claire Hopkins, Professor
of Rhinology at King's College London and Consultant ENT Surgeon at
Guy's & St Thomas' NHS Foundation Trust, has reported a
retrospective study showing that using Steriwave in her endoscopic
sinus surgery patients led to antibiotic use across all her
patients dropping from 22% to less than 5% - a 77% reduction. Professor Hopkins has been using Steriwave
routinely to nasally decolonise her endoscopic sinus surgery
patients at London Bridge Hospital since 2021.
Professor Hopkins commented, "I was
amazed that studies show that by treating the nose you can reduce
spinal surgical site infections - so it seemed an ideal way to
reduce the risk of post-operative infection after nasal surgery. I
have seen a significant reduction in post-operative infections
requiring antibiotics, which is good for the patients, reducing the
risk of antibiotic-related side effects, and important to help
prevent ever-increasing antibiotic resistance. It needs formal
controlled studies to further evaluate the effectiveness but I am
impressed with the difference that I have seen in my
practice."
Interview with Professor
Hopkins:
Steriwave prevents sinonasal SSIs
Carolyn Cross CEO of Ondine
commented, "In an era of rising drug resistance, antibiotic
stewardship is of great importance. Sinus surgery is
typically associated with high rates of routine post-operative
antibiotic prescribing in order to reduce the risk of
post-operative infection. Reducing antibiotic usage is important to
curb rising antimicrobial resistance and preserve antibiotics'
effectiveness when there is no other solution. We are pleased to be
supporting Professor Hopkins' development and adoption of important
new infection control procedures that enable a marked reduction in
antibiotic use in sinus surgery patients."
Canadian hospitals have been using Ondine's
light-activated antimicrobial to reduce post-surgical infections
for over 10 years without evidence of resistance generation or
patient safety issues. Results
presented at the
the prestigious SPIE Photonics West conference in San
Francisco, California showed that treatment with Ondine's
Steriwave® Nasal Photodisinfection System significantly reduces
pathogens - viruses, bacteria and fungi - in the nose without
producing long-term adverse effects on the nasal microbiome. This
is an important finding to allay potential concerns as to a
possible side-effect of Steriwave treatment, which has been used in
over 150,000 patients with no serious adverse events reported.
Steriwave was selected as a 2024 SPIE Prism Awards finalist in the
'Biomedical' category.
" END"
Ondine Biomedical
Inc.
|
|
Carolyn Cross, CEO
|
+001 (604) 665 0555
|
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
Aubrey Powell, Asha Chotai, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine
Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences
company and leader innovating light-activated antimicrobial
therapies (also known as 'photodisinfection'). Ondine has a
pipeline of investigational products, based on its proprietary
light activated technology, in various stages of development.
Ondine's light activated technology for nasal
decolonisation has a CE mark in Europe and the UK and is approved
in Canada and several other countries under the name Steriwave®. In
the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical
indications such as chronic sinusitis, ventilator-associated
pneumonia, burns, and many other indications.
About
Steriwave®
Ondine's Steriwave® nasal photodisinfection system is
a patented technology using a proprietary light-activated
antimicrobial (photosensitizer) to destroy bacteria, viruses, and
fungi colonizing the nose. The photodisinfection treatment is
carried out by a trained healthcare professional and is an easy to
use, painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the
area with a specific wavelength of red laser light for less than
five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens without
causing long-term adverse effects on the nasal microbiome. A key
benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81%[i]-is that
pathogens do not develop resistance to the therapy.
Nasal decolonization is recommended in the 2016 WHO
Global guidelines for the prevention of surgical site
infections,[ii] and the Society for Healthcare
Epidemiology of America (SHEA) guidelines, published in May 2023,
recommend nasal decolonization for major surgical
procedures.[iii]